Bio Rising
Venture Firms Rediscover Biotech

Center for Economic Development

Carnegie Mellon University
Center for Economic Development
Regional Enterprise Tower
425 Sixth Avenue, Suite 1110
Pittsburgh, PA 15219

Phone:  412.765.0280
Fax:  412.765.0290
www.smartpolicy.org

Smart Policy for Innovative Regions

September 2002
Bio Rising: Venture Firms Rediscover Biotech

By Lena Andrews and Jerry Paytas, Ph.D.

Venture capital investment in the biotechnology sector has grown a great deal over the past decade. Between 1991 and 2001, total venture capital funding of biotechnology companies in the United States increased by 842%. Between 1995 and 2000, funding increased by an average of 37% per year. In 2000, total biotechnology funding peaked at $6 billion. A 7.8% decline in 2001 was far less severe than the 61.2% decline in total venture investment in the nation in 2001.

Figure 1

Total VC Biotech Funding (with percentage of all VC funding), 1982-2001

Source: Venture Economics

Where the deals are....

Biotechnology companies receiving venture funding were concentrated in five regions. These regions accounted for 53.4% percent of total biotech funding between 1991 and 2001. Of the five, Boston had the largest share at 13.7% of total US bioventure VC; San Diego had the second largest share, 12.2%. San Diego has started to erode Boston’s lead in venture funding as it edged out Boston with 13.6% of the venture investment for 2001 compared to 13.3% for its East Coast rival. Forty-six percent of all biotech venture funding in 1991-2001 went to companies in California. Of the top ten MSAs receiving biotechnology venture funding in the last decade, only Philadelphia, Raleigh-Durham-Chapel Hill, and Middlesex-Somerset-Hunterdon are not located on coasts.
Other people’s money…

Venture capital firms making biotechnology investments were located in a small number of regions. The most active venture firms over the past two decades are located in San Francisco, New York, Boston, Trenton, Stamford-Norwalk, San Jose, Baltimore, and Chicago. Many of the regions with very active biotech investors are exporters of biotech capital, while many of the top markets have a relatively small community of investors.

**Most Active Bio Investors**

1. San Francisco
2. New York
3. Boston
4. Trenton
5. Stamford-Norwalk
6. San Jose
7. Baltimore
8. Chicago

*Italics indicate venture “exporters”*

**Top Markets for Bio Investment**

1. Boston
2. San Diego
3. San Francisco
4. San Jose
5. Oakland
6. Raleigh-Durham-Chapel Hill
7. Philadelphia
8. Orange County

Bold indicates venture “importers”
In fact, most venture capital flowed between MSAs. Of the 1,739 biotechnology companies in the U.S. that received venture funding between 1982 and 2001, only 191, or 11.0%, did not receive any venture funding from outside of the MSA. This confirms earlier findings by Florida and Smith (1993) of high degrees of capital mobility within venture capital markets.\(^\text{ii}\)

**Table 1: Sources of Biotech Venture Capital Funding, 1982-2001**

<table>
<thead>
<tr>
<th>Source of Funding</th>
<th>Number of Biotech Companies</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Entirely Local (same MSA)</td>
<td>191</td>
<td>11.0%</td>
</tr>
<tr>
<td>Mix of Local and Nonlocal</td>
<td>496</td>
<td>28.5%</td>
</tr>
<tr>
<td>Entirely Nonlocal</td>
<td>1052</td>
<td>60.5%</td>
</tr>
</tbody>
</table>

*Source: VentureEconomics, Analysis by the Center for Economic Development.*

---

**Other Venture Capital Reports from the CED:**

- Technology in Pittsburgh: Trends in Biotechnology Investment
- Venture Capital Floods Pittsburgh
- Recent Venture Capital Trends in Pittsburgh
- Venture Capital Disbursements by Region
- Venture Capital in the United States

---

**Other Reports on the Biotechnology Sector from the CED**

- A Biotechnology Action Plan for Southwestern PA

---

\(^\text{i}\) Calculated using total number of deals by firm MSA, 1982-present.


\(^\text{iii}\) This data does not include investments in companies by undisclosed firms or firms for which MSA data was not available (20% of the original data set).